Latest News

The Fondazione Telethon agent, etuvetidigene autotemcel, significantly reduced severe infections and bleeding events in clinical studies.

Deevyashali Parekh, MBBS, an internal medicine resident at SUNY Upstate Medical University Hospital, discussed findings from a patient population traditionally excluded from clinical trials for CAR-T.

ImmunoLogic cohost Janna Minehart, MD, discussed a few exciting immunotherapy sessions she attended at ASH's Annual Meeting.

Crawford Strunk, MD, an associate staff member at the Cleveland Clinic, discussed the institution's experience with integrating use of exa-cel and lovo-cel.

Crawford Strunk, MD, an associate staff member at the Cleveland Clinic, discussed a study he presented at ASH’s 2025 Annual Meeting.

AZD0120, a dual-targeted CAR T-cell therapy, shows high efficacy in treating relapsed multiple myeloma, achieving a 96% response rate.

Review top news and interview highlights from the week ending December 5, 2025.

Colleen Caleshu, MS, CGC, the senior director of research and real world data at Genome Medical, discussed a session she chaired at the NSGC Annual Conference.

The agency's decision was based on results from an r/r MZL cohort in the phase 2 TRANSCEND FL clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed lessons that should guide the next generation of developers and regulators entering the field.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about how our understanding of advanced therapeutics is still evolving.

In episode 7 of ImmunoLogic, Anusha Kalbasi, MD, discussed his research on the use of IL-9 to enhance CAR-T efficacy.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending November 28, 2025.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about streamlining collaboration to speed up advancement of new therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA also added a new Warnings & Precaution for heightened susceptibility to serious infections caused by immunosuppression.

According to Novartis, it is the first gene replacement therapy to have been approved “for this broad population.”

The NSGC president-elect spoke on the evolving role of genetic counselors, emphasizing personalized care, gene therapy advancements, and the need for multidisciplinary integration in healthcare.

Review top news and interview highlights from the week ending November 21, 2025.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about strategies for streamlining development of novel therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

This finding came from an analysis of 37 patients treated in the phase 1/2 LEGEND trial.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed major friction points in cell and gene therapy development and uptake in the current day.

The chair of the Division of Hematology at Mayo Clinic discussed practical considerations for the introduction of cell therapies for the treatment of hematologic malignancies.

According to Intellia, the FDA placed clinical holds on both MAGNITUDE and MAGNITUDE-2 on October 29, 2025.

Review top news and interview highlights from the week ending November 7, 2025.